AstraZeneca Pauses Coronavirus Vaccine Trial September 2020
An Unexplained Illness To A UK Participant In Leading Coronavirus Vaccine Trial By AstraZeneca and Oxford University Has Sparked a Greater Understanding Of The Potential Of Vaccine Trials To Fail At Even Relatively Advanced Stages
The pause in Astrazeneca vaccine trial is not fatal. Indeed pauses to enable investigation of illnesses in participants is fairly common and a good safety measure. However it can also be fatal as is evidenced by fall in value of AstraZeneca share value. More widely it is a salutatory reminder that we may not be as close to a solution to the coronavirus pandemic as everybody hopes.